(Q35186747)

English

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

0 references

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

0 references

0 references

treatment of cancer

0 references

1 reference

based on heuristic

inferred from title

Early Breast Cancer Trialists' Collaborative Group

1

object named as

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Vaughan M. Evans

1 reference

ORCID Public Data File 2021

Michelino De Laurentiis

1 reference

ORCID Public Data File 2021

author name string

C Davies

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

J Godwin

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

R Gray

4

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

M Clarke

5

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

D Cutter

6

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

S Darby

7

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

P McGale

8

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

H C Pan

9

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

C Taylor

10

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Y C Wang

11

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

M Dowsett

12

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

J Ingle

13

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

R Peto

14

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

language of work or name

0 references

publication date

28 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

378

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

9793

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

771-784

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

describes a project that uses

0 references

Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

13 July 2018

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

13 July 2018

A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

13 July 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

13 July 2018

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

13 July 2018

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

13 July 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

13 July 2018

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

13 July 2018

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

13 July 2018

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Gro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol I

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3163848

27 September 2018

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960993-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960993-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960993-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960993-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960993-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960993-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960993-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21802721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh

1 reference

https://pubmed.ncbi.nlm.nih.gov/21802721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Reevaluation of indications for adjuvant hormone therapy in primary breast cancer with high metastatic risk]

1 reference

https://pubmed.ncbi.nlm.nih.gov/21802721

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S0140-6736(11)60993-8

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35186747&oldid=1994664410"